newsfilter
← Latest News
GlobeNewswire·

Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

Tuspetinib (TUS) Combination with Venetoclax (VEN) Clinical Findings Highlighted TUS Targets VEN Resistance Mechanisms to Re-sensitize VEN Failure Patients to VEN44% ORR with TUS/VEN in Difficult-to-Treat VEN Failure